MAS Collateralised Reinsurance and Insurance-Linked Securities Consultation 2026: What Insurers Should Do Now

The Singapore insurance-linked securities framework is about to gain a new structural option. On 7 July 2026 the Monetary Authority of Singapore (MAS) issued a consultation on a legislative framework for protected cell companies (PCCs), with insurance-linked securities (ILS), collateralised reinsurance, captive insurance and sovereign risk pools named as the initial use cases. Sponsors, cedants and reinsurers considering Singapore as an ILS domicile should use the consultation period and the lead time before commencement to test their structures, governance and capital assumptions against what MAS has proposed.

This article sets out what the consultation covers, how it differs from the existing special purpose reinsurance vehicle route, and the preparation steps worth taking now. Details of the final regime may change after MAS reviews feedback, so treat the points below as planning assumptions to be confirmed against the published consultation paper and any subsequent policy response.

What MAS Has Proposed

A protected cell company is a single legal entity divided into a core and a number of cells. Each cell holds its own assets and liabilities, and the proposed framework is designed so that the assets of one cell are ring-fenced from the creditors of other cells and of the core. For ILS and collateralised reinsurance, the practical appeal is that separate transactions can sit in separate cells inside one vehicle, rather than each deal requiring its own newly incorporated company.

MAS has described the framework as a means of supporting the growth of alternative risk transfer in insurance. The initial use cases it identified are captive insurance, ILS and sovereign risk pools. Market commentary has suggested the regime could be in place by 2028, but that timing should be confirmed against MAS publications before it is built into any project plan.

Readers should obtain the consultation paper directly from MAS and confirm the closing date for responses. Where a firm intends to submit feedback, the practical work of mapping proposals to its own transaction structures needs to start well ahead of that date.

How This Differs From the Existing SPRV Route

Singapore already has a framework for special purpose reinsurance vehicles (SPRVs), which are licensed as special purpose reinsurance vehicles to issue insurance-linked securities such as catastrophe bonds. That framework has supported Singapore-domiciled catastrophe bond issuance, supported by the MAS ILS Grant Scheme.

The special purpose reinsurance vehicle Singapore route works well for large, repeatable programmes where the cost of establishing a standalone vehicle is absorbed by the size of the issuance. It is less efficient for smaller or bespoke transactions, such as sidecars and collateralised reinsurance placements, where incorporation, licensing and ongoing administration of a separate vehicle can erode the economics of the deal.

The PCC proposal targets that gap. A single PCC with multiple cells could, in principle, host several transactions at lower marginal cost. The trade-off is that the structure introduces its own questions: how cell segregation is evidenced and maintained, how the core is capitalised and governed, and what happens to the other cells if one cell fails. Investors and rating agencies will examine these points closely, and sponsors should expect to answer them in offering documents.

The ILS Grant Scheme and Its Interaction With the Framework

MAS operates an ILS Grant Scheme that runs from January 2026 to December 2028. According to the MAS scheme page, it can cover up to 70 percent of upfront issuance costs for new collateralised reinsurance and sidecar transactions, subject to a cap of S$500,000 per deal. Eligibility criteria, including requirements relating to the nature of the risks and the use of Singapore-based service providers, are set out by MAS and should be checked against the current scheme terms before any application.

For sponsors, the grant scheme and the proposed PCC framework point in the same direction: lowering the cost of the first transactions and building a local market for collateralised reinsurance. Planning a transaction so that it is eligible for the grant, and flexible enough to migrate into a cell structure once available, is a reasonable position to take while the legislation is pending.

Implications for Cedants

Cedants buying collateralised reinsurance remain subject to existing requirements on reinsurance arrangements, risk transfer and credit for reinsurance in their capital calculations. A cell-based counterparty does not change the principle that capital relief depends on the reinsurance arrangement genuinely transferring risk and on the counterparty arrangements being legally enforceable and fully collateralised.

Cedants should consider the following points when evaluating a PCC-based counterparty:

• Legal opinion on cell segregation and the enforceability of the ring-fence in an insolvency of the core or another cell.
• Collateral terms, including eligible assets, valuation, top-up mechanics and the treatment of trust or custody arrangements.
• Basis risk and trigger design, particularly where the transaction uses parametric or index triggers.
• Treatment of the arrangement under the risk-based capital framework, including how reinsurance recoverables from collateralised structures are recognised.
• Reporting and disclosure to MAS where the arrangement is material to the insurer's risk profile.

Insurers should also reflect the new counterparty type in their reinsurance risk management policy and in the ORSA, since concentration, counterparty and legal risks differ from those of a conventional rated reinsurer.

Implications for Sponsors and Reinsurers

Sponsors, including reinsurers and asset managers, should model the economics of a cell-based structure against a standalone SPRV. The inputs include set-up and licensing costs, annual administration, audit, directors and service provider fees, and the capital that the core is likely to need. Until MAS publishes capital and governance parameters, these inputs will be assumptions, and sensitivity ranges are more useful than point estimates.

Reinsurers considering fronting or supporting cell-based transactions should assess the following:

• Whether the proposed core capital and governance requirements fit their group structure.
• The role of the manager or administrator and any outsourcing obligations that attach to it.
• Investor reporting, valuation and audit expectations at cell level.
• Tax treatment, which sits outside MAS regulation but affects investor appetite and should be confirmed with tax advisers.

What to Do Now

Several preparation steps are available before the final framework is known.

First, read the consultation paper in full and prepare a gap analysis of each question MAS has asked. Firms with live or planned ILS activity should decide whether to respond, and what facts and data they can offer to support their position.

Second, map existing and pipeline transactions to the likely structures: standalone SPRV, cell of a PCC, or conventional collateralised reinsurance with a licensed reinsurer. For each, list the regulatory permissions required, the parties involved and the approvals that would apply.

Third, review governance. A PCC will need a board that understands cell-level accountability, conflicts between cells, and the obligation to protect segregation. Sponsors should identify directors, officers and service providers with relevant ILS experience.

Fourth, review risk management documentation. Insurers expecting to cede to or sponsor such structures should update reinsurance strategy, counterparty limits and stress scenarios, and confirm how the ORSA will capture legal and collateral risks.

Fifth, engage early with MAS where a novel structure is contemplated. Informal discussions before a formal application help identify issues at a stage when they are still inexpensive to resolve.

Licensing and Market Entry Considerations

Foreign sponsors and reinsurers new to Singapore will need to understand which activities in the structure are regulated and by whom. Depending on the design, regulated activities may include carrying on reinsurance business, issuing securities, fund management and acting as manager or administrator. Each carries its own licensing, capital and conduct requirements under the Insurance Act 1966, the Securities and Futures Act 2001 and related regulations and notices. Mapping these early avoids discovering late in a transaction that a party needs a licence, a waiver or a local presence that was not planned for.

Where the ultimate sponsor is a corporate group seeking a captive solution rather than an ILS transaction, the same cell-based framework may become relevant, and the group should consider how it compares with a conventional captive licence under the existing regime.

Next Steps

The Singapore insurance-linked securities framework is moving from a single-vehicle model towards a more flexible one, and early preparation is likely to give sponsors and cedants a head start once the rules are final. If you are assessing a collateralised reinsurance or ILS transaction in Singapore, or deciding whether to respond to the MAS consultation, speak to Alpha Consultant about our regulatory licensing advisory and our capital markets advisory services.